Ziopharm Oncology (ZIOP -6.2%
) drops following a blog report
in Forbes.com that accuses the company of failing to disclose an FDA warning letter. The blogger, an investor short on the stock, says the FDA admonished a clinical investigator hired by ZIOP
for multiple violations in a mid-stage study of Palifosfamide, its investigational cancer drug. The study in question has since advanced into a late-stage trial with results expected before 2013.